|Applications||ICC/IF, IP, WB|
Not tested in other applications.
*Optimal dilutions/concentrations should be determined by the researcher.
|Predicted Target Size||33 kDa (note)
|Observed Size||42/44 kDa.
The observed M.W. is based on the following publication. PMID:9597000
|Positive Controls||A431 , H1299 , HeLa , HepG2 , Molt-4 , Raji , Neuro 2A , GL261 , C8D30 , NIH-3T3 , BCL-1 , Raw264.7 , C2C12 , PC-12 , Rat2 , C2C12|
(Please refer to the vial label for the specific concentration)|
|Purification||Purified by antigen-affinity chromatography.|
|Full Name||SET nuclear oncogene|
|Product Description||Rabbit Polyclonal antibody to SET (SET nuclear oncogene)|
|Synonyms||2PP2A antibody, I2PP2A antibody, IGAAD antibody, IPP2A2 antibody, PHAPII antibody, TAF-I antibody, TAF-IBETA antibody, SET antibody, inhibitor-2 of protein phosphatase-2A antibody, phosphatase 2A inhibitor I2PP2A antibody, inhibitor of granzyme A-activated DNase antibody, HLA-DR-associated protein II antibody, SET translocation (myeloid leukemia-associated) antibody, "Template-Activating Factor-I, chromatin remodelling factor antibody", protein SET antibody, protein phosphatase type 2A inhibitor antibody, SET nuclear oncogene antibody|
|Cellular Localization||Cytoplasm , cytosol , Endoplasmic reticulum , Nucleus , nucleoplasm |
|Specificity||Knockdown/Knockout validation was supported by customer review data.|
|Immunogen||Recombinant protein encompassing a sequence within the center region of human SET. The exact sequence is proprietary.|
|Species Reactivity||Human, Mouse, Rat|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Xenopus laevis, Pig, Chicken, Bovine|
|Predict Reactivity Note||Xenopus laevis (99%), Pig (100%), Chicken (100%), Bovine (99%)|